Cardinal Health (CAH) closed the latest trading day at $128.88, indicating a -1.2% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 3.46%.

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

The stock's rise snapped a four-day losing streak.

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health ...

Following recent U.S. Food and Drug Administration (FDA) approval 2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability across a wide ...

Opioid settlements with companies like Purdue Pharma, Walmart, and Johnson & Johnson have led to headline-grabbing ...

In a report released on April 4, Michael Cherny from Leerink Partners maintained a Hold rating on Medpace Holdings (MEDP – Research Report).

This was the stock's third consecutive day of losses.

The global Traditional Wound Care Market , valued at US$7.15 billion in 2024, is forecasted to grow at a robust CAGR of 4.2%, reaching US$7.42 billion in 2025 and an impressive US$9.12 billion by 2030 ...

Cardinal Health Inc. hit a new 52-week high, surpassing its previous peak of $138.62, which the company reached on March 31st ...